Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Aeglea BioTherapeutics, Inc. (AGLE)
Last aeglea biotherapeutics, inc. earnings: 8/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aegleabio.com/investor-overview
Company Research
Source: GlobeNewswire
AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today reported financial results for the third quarter ended September 30, 2018. “2018 continues to be a highly productive year for Aeglea as we advance our clinical experience in pegzilarginase and demonstrate our drug hunting capabilities in rare genetic diseases," said Anthony G. Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. “Our data in Arginase 1 Deficiency (ARG1-D) continues to demonstrate rapid, well-tolerated and sustainable control of arginine that corresponds with significant improvements in patients. This progress with pegzilarginase puts us in a strong position as we look to initiate our pivotal trial in ARG1-D in the first half of 2019.” Recent Highlights Pegzilarginase in Arginase 1 Deficiency: S
Show less
Read more
Impact Snapshot
Event Time:
AGLE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGLE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGLE alerts
High impacting Aeglea BioTherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics